103203-54-9

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-Methoxyphenoxy)benzoic acid is used as a building block for the synthesis of various pharmaceuticals, contributing to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
4-(2-METHOXYPHENOXY)BENZOIC ACID is used as a starting material for the synthesis of agrochemicals, which can be employed in the development of new pesticides, herbicides, and other agricultural products to improve crop yield and protect plants from pests.
Used in Materials Science:
4-(2-Methoxyphenoxy)benzoic acid is used as a component in the development of new materials, such as polymers and composites, due to its unique chemical structure and properties. This can lead to the creation of innovative materials with improved performance characteristics for various applications.
Used in Research Applications:
4-(2-METHOXYPHENOXY)BENZOIC ACID serves as a valuable research tool in various scientific fields, including chemistry, biology, and materials science, for studying its properties, interactions, and potential applications in the development of new products and technologies.

Upstream product

• 578-57-4 2-bromoanisole 
• 107922-35-0 3,5-diiodo-4-(2-methoxy-phenoxy)-benzoic acid methyl ester 
• 99-96-7 4-hydroxy-benzoic acid 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 78338-67-7 4-(2'-methoxyphenoxy)benzonitrile 
• 1194-02-1 4-fluorobenzonitrile 
• 459-57-4 4-fluorobenzaldehyde 
• 78725-48-1 4-(2-methoxyphenoxy)benzaldehyde 
• 5633-98-7 potassium guaiacolate 
• 106-38-7 para-bromotoluene 
• 90-05-1 2-methoxy-phenol 
• 108621-37-0 4-(2-methoxy-phenoxy)-3,5-dinitro-benzoic acid methyl ester 
• 2552-45-6 methyl 4-chloro-3,5-dinitrobenzoate 
• 110-86-1 pyridine 

Downstream Products

• 913829-13-7 (4-ethyl-5-{5-[4-(2-methoxyphenoxy)phenyl]-1,2,4-oxadiazol-3-yl}-2-thienyl)methanol 
• 1436378-51-6 N-(1S)-1-{[(3S)-4-(3-hydroxyphenyl)-3-methylpiperazin-1-yl]-methyl}-2-methylpropyl-4-(2-methoxyphenoxy)benzamide 
• 1436378-52-7 N-(1S)-1-{[(3S)-4-(3-hydroxyphenyl)-3-methylpiperazin-1-yl]-methyl}-2-methylpropyl-4-(2-hydroxyphenoxy)benzamide 
• 1446443-97-5 N-[(dimethylamino)sulfonyl]-4-(2-methoxyphenoxy)benzamide diethylamine salt 
• 1377995-67-9 C₂₃H₃₀N₂O₃ 

Relevant academic research and scientific papers

Beyond Basicity: Discovery of Nonbasic DENV-2 Protease Inhibitors with Potent Activity in Cell Culture

The viral serine protease NS2B-NS3 is one of the promising targets for drug discovery against dengue virus and other flaviviruses. The molecular recognition preferences of the protease favor basic, positively charged moieties as substrates and inhibitors, which leads to pharmacokinetic liabilities and off-target interactions with host proteases such as thrombin. We here present the results of efforts that were aimed specifically at the discovery and development of noncharged, small-molecular inhibitors of the flaviviral proteases. A key factor in the discovery of these compounds was a cellular reporter gene assay for the dengue protease, the DENV2proHeLa system. Extensive structure-activity relationship explorations resulted in novel benzamide derivatives with submicromolar activities in viral replication assays (EC50 0.24 μM), selectivity against off-target proteases, and negligible cytotoxicity. This structural class has increased drug-likeness compared to most of the previously published active-site-directed flaviviral protease inhibitors and includes promising candidates for further preclinical development.

1-substituted 4-arylpiperazine as kappa opioid receptor antagonists

Provided are compounds represented by the formula: where R, Y3, R1, R2, R3, R4, R6, G, R7, E1, E2, A, B, W, X, Y and Z are as defined herein.

N-AMINOSULFONYL BENZAMIDES

The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulphonamide Nav 1.7 inhibitors of formula (I) or a pharmaceutically acceptable salt thereof, wherein Z, R1a, R1b, R2, R3, R4 and R5 are as defined in the description. Nay 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain

Discovery of N-{4-[(3-hydroxyphenyl)-3-methylpiperazin-1-yl]methyl-2- methylpropyl}-4-phenoxybenzamide analogues as selective kappa opioid receptor antagonists

There is continuing interest in the discovery and development of new κ opioid receptor antagonists. We recently reported that N-substituted 3-methyl-4-(3-hydroxyphenyl)piperazines were a new class of opioid receptor antagonists. In this study, we report the syntheses of two piperazine JDTic-like analogues. Evaluation of the two compounds in an in vitro [35S] GTPγS binding assay showed that neither compound showed the high potency and κ opioid receptor selectivity of JDTic. A library of compounds using the core scaffold 21 was synthesized and tested for their ability to inhibit [35S]GTPγS binding stimulated by the selective κ opioid agonist U69,593. These studies led to N-[(1S)-1-{[(3S)-4-(3-hydroxyphenyl)-3- methylpiperazin-1-yl]methyl}-2-methylpropyl]-4-phenoxybenzamide (11a), a compound that showed good κ opioid receptor antagonist properties. An SAR study based on 11a provided 28 novel analogues. Evaluation of these 28 compounds in the [35S]GTPγS binding assay showed that several of the analogues were potent and selective κ opioid receptor antagonists.

1-SUBSTITUTED 4-ARYLPIPERAZINE AS KAPPA OPIOID RECEPTOR ANTAGONISTS

Provided are compounds represented by the formula: where R, Y3, R1,R2, R3, R4, R6, G, R7, E1, E2, A, B, W, X, Y and Z are as defined herein.

Discovery of CS-2100, a potent, orally active and S1P3-sparing S1P1 agonist

S1P3-sparing S1P1 agonists have attracted attention as a suppressant of autoimmunity with reduced side effects. Our synthetic efforts and extensive SAR studies led to the discovery of 10b named CS-2100 with the EC50 value of 4.0 nM for human S1P1 and over 5000-fold selectivity against S1P3. The in vivo immunosuppressive efficacy was evaluated in rats on host versus graft reaction and the ID 50 value was determined at 0.407 mg/kg. The docking studies of CS-2100 with the homology model of S1P1 and S1P3 showed that the ethyl group on the thiophene ring of CS-2100 was sterically hindered by Phe263 in S1P3, not in the case of Leu276 in S1P1. This observation gives an explanation for the excellent S1P3-sparing characteristic of CS-2100.

HETEROCYCLIC COMPOUND

[Object] To provide a novel compound having an excellent immunosuppressive activity with low toxicity or a pharmacological salt thereof. [Means to achieve the object] A compound having general formula (I) shown below or a pharmacologically acceptable salt thereof, or a pharmacologically acceptable prodrug thereof [wherein A represents a carboxyl group, or the like, B represents a hydrogen atom, or the like, V represents a single bond, a methylene group, or the like, n represents an integer of from 0 to 2, W represents a 5- to 7-membered heterocyclic group, or the like, Z represents a group selected from Substituent group A, or the like, and Substituent group A represents the group consisting of a halogen atom, a C1-C6 alkyl group, a C3-C7 cycloalkyl group.